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OBJECTIVE: To estimate the annual cost of chronic
obstructive pulmonary disease (COPD) to the California
Medicaid (“Medi-Cal”) program. METHODS: This
study employed a retrospective matched cohort design
and administrative claims data for a 20% random sample
of Medi-Cal recipients. Patients selected were 50+ years
of age, with a diagnosis of COPD in 2000, and eligible
for Medicaid as of January 1, 2000. The comparison
cohort consisted of patients without COPD matched on
age, gender, race, and dual (Medicare/Medicaid) eligibil-
ity status. The cost of COPD was estimated as the dif-
ference in mean Medi-Cal payments between the COPD
and comparison cohorts during 2000. RESULTS: A total
of 12,538 patients with COPD met study inclusion crite-
ria. Approximately 8% were diagnosed with emphysema,
37% with chronic bronchitis, and 55% with unclassiﬁed
chronic airway obstruction. COPD patients and their
matched controls (n = 12,538) averaged 70 years of age;
55% were female, 55% were white, and 65% were 
eligible for Medicare beneﬁts. Charlson comorbidities,
especially congestive heart failure and vascular disease,
were more common in the COPD cohort. The proportion
of patients hospitalized was higher in the COPD cohort
both for respiratory-related conditions (19% vs. 2% for
controls, p < 0.05) and for any reason (38% vs. 15%, 
p < 0.05). The annual per-patient cost of COPD was 
estimated to be $3185 ($9537 for the COPD cohort
minus $6352 for the control cohort), 55% ($1765) of
which was due to hospitalizations. Annual per-patient
costs of COPD were $4679 for patients <65 years versus
$2322 for those 65+ years. Disease costs also were higher
among patients with emphysema ($7094) versus chronic
bronchitis ($3131) or unclassiﬁed chronic airway
obstruction ($2694). CONCLUSIONS: On an aggregate
basis, COPD costs the Medi-Cal program $200 million
annually. Acute hospitalizations drive costs, despite cov-
erage available through Medicare for the use of these ser-
vices by elderly patients.
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NONCONFORMANCE WITH NCEP-ATP III
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OBJECTIVES: According to National Cholesterol 
Education Program—Adult Treatment Panel III, baseline
lipid and lipoprotein measurements should be docu-
mented prior to initiating lipid-lowering therapy. This
study describes the patterns of nonconformance to the
measurement guideline, and assesses whether the non-
conformance is associated with emergency department or
hospital utilization. METHODS: Data were obtained
from an administrative database of a managed care orga-
nization. The study sample consisted of all continuously
eligible adult patients newly initiated with statins from
June 1998–June 2000. All patients were followed for one
year. Patients without lipid or lipoprotein measurement
within six months prior to or on initiation date were iden-
tiﬁed as nonconforming. CPT codes were used to identify
lipid/lipoprotein measurements. Cox proportional hazard
regression evaluated the impact of laboratory nonconfor-
mance to time to the ﬁrst emergency department or 
hospital utilization. Logistic regression was performed to
assess the risk factors for nonconformance. RESULTS:
Among 25,854 selected patients, 10,205 (39.5%) patients
have any claim record for lipid/lipoprotein measurement
before initiation of statin therapy. After controlling for 38
covariates including patient demographics, payer type,
physician specialty, previous drug, and medical utilization
pattern, and comorbidities, patients with nonconfor-
mance have 9.2% higher likelihood of earlier emergency
department or hospital utilization conforming patients 
(p = 0.006). Logistic regression revealed that older age,
HMO in contrast to PPO are risk factors of nonconfor-
mance, while prescribing physician specialty (cardiology
or internal medicine), previous use of Niacin, and patients
with comorbidities are more likely to receive baseline
measurement. CONCLUSIONS: The use of administra-
tive claims to determine conformance with ATP III on
lipid/lipoprotein measurement is subject to reporting lim-
itations, but it appears that recorded rate of conformance
to the guideline recommendation is low. Nonconfor-
mance to the guideline recommendation is signiﬁcantly
associated with emergency department or hospital 
utilization.
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OBJECTIVE: Clopidogrel is an antiplatelet agent that 
has been shown to reduce the risk of ischemic stroke 
(IS), myocardial infarction (MI), and vascular death
(“atherothrombotic events”) compared with aspirin in
patients with recent IS, recent MI, or symptomatic periph-
eral arterial disease (PAD). The objective of this study was
to estimate the cost-effectiveness of clopidogrel versus
aspirin in these patients. METHODS: We developed a
Markov model in which patients with recent 
IS, recent MI, or PAD were assumed to receive lifelong
therapy with clopidogrel or aspirin. Reduction in risk of
atherothrombotic events for clopidogrel (vs aspirin) was
estimated using data from the Clopidogrel versus Aspirin
in Patients at Risk of Ischemic Events (CAPRIE) clinical
trial. Costs considered in the model included those of
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antiplatelet therapy, inpatient and outpatient treatment of
ischemic stroke, MI, and bleeds, and long-term care for
patients with disability. We examined the cost-effective-
ness of clopidogrel for subgroups of patients deﬁned on
the basis of age at therapy initiation (55, 65, and 75 years)
and gender. Cost-effectiveness was assessed using the
ratio of the difference (clopidogrel minus aspirin) in
expected lifetime medical-care costs to the corresponding
difference in life expectancy. A 3% discount rate was
used. RESULTS: One hundred patients with recent IS,
recent MI, or PAD receiving clopidogrel would experience
4.5–6.3 fewer atherothrombotic events and 3.6–8.7 
fewer bleeds over their lifetimes in comparison with 100
patients receiving aspirin. The expected gain in life-years
ranges from 0.33–0.69 per patient. Expected total life-
time medical-care costs are $9,222–$16,850 higher for 
clopidogrel patients. Cost-effectiveness of clopidogrel
ranges from $40,204–$49,107 per life-year saved, and is
sensitive to the assumed risk reduction for clopidogrel.
CONCLUSION: Clopidogrel is cost-effective versus
aspirin in patients with recent IS, recent MI, or PAD.
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OBJECTIVE: This retrospective, observational, health
plan administrative claims database study examined
treatment patterns, resource utilization, and costs of
venous thromboembolic (VTE) disease [deep venous
thrombosis (DVT) and pulmonary embolism (PE)] in a
managed care setting. METHODS: Medical and phar-
macy claims of patients with a newly diagnosed VTE
event were gathered from 2 US health plan databases
from January 1997 through September 2001. Inclusion
criteria included a VTE event between January 1, 1998
and December 31, 2000 (no VTE diagnosis or anti-
coagulation therapy 3 months prior to index VTE event),
continuous health plan enrollment 6 months prior and 12
months after index VTE event, and a VTE medication ﬁll
after index date. Medical and pharmacy care associated
with recurrent VTE or bleeding events were based on each
patient’s index VTE event, and detailed by type, number,
and cost. Costs of recurrent episodes were calculated
using general linear model regression and bootstrap tech-
niques. RESULTS: A total of 2147 patients (DVT = 1499;
PE = 373; DVT&PE = 275) were enrolled (mean age =
61.6 ± 15.9 years, 46.3% male). Median pre- and post-
index observation times were 17.1 and 19.2 months,
respectively. Mean total medical costs for DVT, PE, and
DVT&PE during the index VTE episode were $2293,
$7157, and $3963, respectively. Warfarin treatment was
administered for a mean 6.3 months at an average cost
of $145. The annualized rates and adjusted costs of post-
index VTE events were 9.48% and $5331, respectively,
for VTE episodes; and 5.52% and $8978, respectively, 
for bleeding episodes. The rate of recurrent VTE episodes
was signiﬁcantly lower in the DVT group than in the PE
group, and the cost of post-index bleed episodes was 
signiﬁcantly higher in the PE group. No other recurrent
rates or cost differences were signiﬁcant. CONCLU-
SIONS: Current therapy for VTE patients is associated
with high costs and signiﬁcant recurrent and adverse
events. Approaches to therapy that increase effectiveness
and decrease risk are needed.
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GENDER VARIATION IN QUALITY OF
PHARMACOLOGIC CARE OF CHILDREN
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Gender variation in diagnosis and treatment of ADHD is
well documented: boys are more likely to be diagnosed
and receive pharmacologic treatment than girls. However,
little is known about gender variation in the quality
(dosage and persistence) of pharmacologic treatment
received by ADHD-diagnosed children. OBJECTIVE: To
examine gender variation in intensity and persistence of
psychostimulant treatment among a national, population-
based sample of ADHD-diagnosed children. METHODS:
We analyzed medical and pharmaceutical claims in the
Medical Expenditures Panel Survey (MEPS) from January
1 through December 31, 1998 among all ADHD-diag-
nosed children (N = 195) aged 4–19 years. Psychostimu-
lant doses were converted to Methylphenidate Equivalent
Units (MEU) according to previously published research
(MEU: 20mg Methylphenidate = 10mg dextroampheta-
mine = 10mg amphetamine salts = 56.25mg Pemoline).
Doses were classiﬁed as high (>15.0mg MEU), medium
(5.0–15.0mg MEU), or low (<5.0mg MEU). Persistence
of treatment was determined by number of prescription
ﬁlls (PF) in a calendar year. Separate weighted logistic and
multiple regression analyses were conducted with MEU
and PF as dependent variables respectively. RESULTS: As
has been reported previously in the literature, males were
1.3 (+/-0.004) times more likely to receive a prescription
for psychostimulants (p < 0.001). However, among 
those receiving any psychostimulant, females were 1.2
(+/-0.008) times more likely than males to receive high
doses (p < 0.001). There was no difference in persistence
of psychostimulant treatment by gender. CONCLUSION:
Whereas girls with AD/HD were less likely to be treated
with psychostimulants, once treated, they received higher
